Enliven Therapeutics to Present at Two Upcoming Investor Conferences
01 June 2023 - 6:55AM
Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a
clinical-stage precision oncology company focused on the discovery
and development of next-generation small molecule kinase
inhibitors, today announced that management will present at the
following investor conferences in June:
Jefferies Healthcare Conference Format: Podium
PresentationDate: Thursday, June 8, 2023Time: 11:00 a.m. ET
The Goldman Sachs Annual Global Healthcare
ConferenceFormat: Fireside ChatDate: Wednesday, June 14,
2023Time: 8:00 a.m. PT
Both the presentation and fireside chat will be
webcast live and can be accessed by visiting the investor relations
section of the Company’s website at
https://ir.enliventherapeutics.com/. Each webcast will be archived
for a period of 30 days following the conclusion of the live
event.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage
biopharmaceutical company focused on the discovery and development
of small molecule inhibitors to help patients with cancer not only
live longer, but better. Enliven aims to address existing and
emerging unmet needs with a precision oncology approach that
improves survival and enhances overall patient well-being.
Enliven’s discovery process combines deep insights in clinically
validated biological targets and differentiated chemistry to design
potentially first-in-class or best-in-class therapies. Enliven is
based in Boulder, Colorado.
Contact:
Enliven Investors & Media:Argot
PartnersEnliven@argotpartners.com
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Oct 2023 to Oct 2024